BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Novartis AG (NVS) Banks on Meningitis Shot to Justify "Oops" Deal; Restructuring, Disposal a Possibility: Analyst


10/1/2012 8:00:36 AM

Novartis AG’s (NOVN) troubled acquisition of Chiron Corp.’s vaccine business has one last hope -- approval of a shot to protect against a meningitis-causing bacteria. Winning European Union backing this year for Bexsero would help salvage the company’s vaccine unit, which it created with the $7.5 billion acquisition of Chiron. Failure, on the other hand, may prompt Novartis to sell or scale back the unit into which the company has poured billions of dollars in funding for little return. And years of delays have raised concerns that Bexsero may be the next to flop.

Read at Bloomberg

Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES